Gallium and other agents in diseases of the lung

doi:10.1053/snuc.2002.124178

Seminars in Nuclear Medicine

Volume 32, Issue 3, July 2002, Pages 193-211

https://doi.org/10.1053/snuc.2002.124178 Get rights and content

The use of gallium for pulmonary diseases is hampered by its relative lack of specificity, typical 1- to 3-day delay between injection and imaging time, and suboptimal imaging characteristics. Other nuclear and nonnuclear imaging modalities, such as ¹⁸F-fluorodeoxyglucose positron emission tomography (PET) and high-resolution chest computed tomography, have replaced gallium in many clinical algorithms. Yet gallium and other radiotracers, such as thallium, sestamibi, and labeled white blood cells, are useful in many specific clinical situations involving lymphoma and other neoplasias, inflammatory processes such as sarcoid and interstitial pneumonia, tuberculosis and other infections, and the acquired immune deficiency syndrome. Gallium and some of the other single-photon agents still have value in establishing a diagnosis, assessing the location and extent of disease, differentiating active disease from chronic scarring, guiding potential biopsy, and determining recurrence and response to therapy in patients with certain lung diseases, particularly when access to PET imaging is not available.

References (145)

BlumJ et al.
A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules
Chest
(2000)
RehmP
Radionuclide evaluation of patients with lymphoma
Radiol Clin North Am
(2001)
ZinzaniPL et al.
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) gallium scan in 50 patients
Blood
(1999)
De MeesterTR et al.
Gallium-67 scanning for carcinoma of the lung
J Thorac Cardiovasc Surg
(1976)
FinkG et al.
Pulmonary carcinoid: Presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature
Chest
(2001)
LynchJP et al.
Pulmonary sarcoidosis
Clin Chest Med
(1997)
SulavikSB et al.
Specificity and sensitivity of distinctive chest radiographic and/or Ga-67 images in the noninvasive diagnosis of sarcoidosis
Chest
(1993)
ManaJ
Nuclear imaging. ⁶⁷Gallium, ²⁰¹thallium, ¹⁸F-labeled fluoro-2-deoxy-D-glucose positron emission tomography
Clin Chest Med
(1997)
KramerEL et al.
Pulmonary applications of nuclear medicine
Clin Chest Med
(1991)
BissonG et al.
Computerbased quantitative analysis of gallium-67 uptake in normal and diseased lungs
Chest
(1983)

ZhuYY et al.

Gallium lung scintigraphy in amiodarone pulmonary toxicity

Chest

(1988)

BekermanC et al.

Gallium-67 citrate imaging studies of the lung

Semin Nucl Med

(1980)

GelbAF et al.

Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis

Chest

(1983)

BrownDG et al.

⁶⁷Gallium scanning in talc-induced pulmonary granulomatosis

Chest

(1980)

SiemsenJK et al.

The use of gallium-67 in pulmonary disorders

Semin Nucl Med

(1978)

EdwardCL et al.

Tumor scanning with Ga-67 citrate

J Nucl Med

(1969)

LavendarJP et al.

Gallium-67 citrate scanning in neoplastic and inflammatory lesions

Br J Radiol

(1971)

LittenbergRL et al.

Gallium-67 for localization of septic lesions

Ann Intern Med

(1973)

NejmeddineF et al.

Ga-67 scintigraphy in B-cell non-Hodgkin's lymphoma: Correlation of Ga-67 uptake with histology and transferrin receptor expression

J Nucl Med

(1999)

Van der WallH et al.

Gallium scintigraphy in tumor diagnosis and management

HofferPB et al.

Demonstration of lactoferrin in tumor tissue from two patients with positive gallium scans

J Nucl Med

(1979)

HofferPB et al.

The association of ⁶⁷Ga and lactoferrin

J Nucl Med

(1977)

TsanMF et al.

Mechanism of gallium localization in inflammatory lesions

J Nucl Med

(1977)

BitarRA et al.

Accumulation of indium-111 labeled neutrophils and gallium-67 citrate in rabbit abscesses

J Nucl Med

(1986)

SfakianakisGN et al.

Comparisons of scintigraphy with In-111 leukocytes and Ga-67 in the diagnosis of occult sepsis

J Nucl Med

(1982)

HigashiT et al.

The relationship between 67Ga accumulation and ATP metabolism in tumor cells in vitro

Eur J Nucl Med

(1989)

TaylorA et al.

A Clinician's Guide to Nuclear Medicine

Abdel-DayemHM et al.

Thallium-201 chloride: A tumor imaging agent

WaxmanAD et al.

Comparison of gallium-67 citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma

J Nucl Med

(1996)

RamannaL et al.

Tl-201 scintigraphy in bone and soft tissue sarcoma: Evaluation of tumor mass and viability

J Nucl Med

(1988)

RosenG et al.

Serial Tl-201 scintigraphy in osteosarcoma: Correlation with tumor necrosis after preoperative chemotherapy

Clin Orthop

(1993)

MatsunoS et al.

Effectiveness of planar image and single photon emission tomography of thallium-201 compared with gallium-67 in patients with primary lung cancer

Eur J Nucl Med

(1992)

KhalkhaliI et al.

Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up

J Nucl Med

(1995)

Villanueva-MeyerJ et al.

Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer

J Nucl Med

(1996)

TaylorA et al.

A Clinician's Guide to Nuclear Medicine

Van der WallH et al.

Gallium scintigraphy in tumor diagnosis and management

RuddersR et al.

The relative roles of gallium-67 citrate scanning and lymphangiography in the current management of malignant lymphoma

Cancer

(1977)

JochelsonMS et al.

Planning mantle radiation therapy in patients with Hodgkin's disease: Role of gallium-67 scintigraphy

AJR Am J Roentgenol

(1988)

TumehSS et al.

Lymphoma: Evaluation with Ga-67 SPECT

Radiology

(1987)

ZinzaniPL et al.

Diagnostic role of gallium scanning in the management of lymphoma with mediastinal involvement

Haematologica

(1999)

IonescuI et al.

Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

Med Oncol

(2000)

UlusakaryaA et al.

Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma

Leuk Lymphoma

(1999)

WeinerM et al.

Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study

Cancer

(1991)

RossleighMA et al.

Pediatric solid tumors: Evaluation by gallium-67 SPECT studies

J Nucl Med

(1990)

Van der WallHVD et al.

The role of thallium scintigraphy in excluding malignancy in bone

Nucl Med Commun

(1993)

LeeVW et al.

Pulmonary Kaposi sarcoma in patients with AIDS: Scintigraphic diagnosis with sequential thallium and gallium scanning

Radiology

(1991)

AlazrakiN et al.

Reliability of gallium scan chest radiography compared to mediastinoscopy for evaluating mediastinal spread in lung cancer

Am Rev Respir Dis

(1978)

MacMahonH et al.

Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer

Cancer

(1989)

BuccheriG et al.

Lack of clinical significance of gallium-67 uptake in non-small cell lung cancer

Eur J Respir Dis

(1987)

YamamotoY et al.

Evaluation of ^99mTc-MIBI to predict chemotherapeutic response in patients with small cell lung carcinoma

Nippon Igaku Hoshasen Gakkai Zasshi

(1996)

Cited by (37)

Imaging of Invasive Fungal Infections- The Role of PET/CT
2023, Seminars in Nuclear Medicine
Citation Excerpt :
Another nonspecific tracer that was previously used extensively in IFD is the SPECT tracer [67Ga]Gallium citrate. This was used for HIV-associated fungal infections such as Pneumocystis jiroveci pneumonia, where it was used in diagnosis when other imaging modalities were equivocal and used to monitor treatment.129,130 FDG PET/CT is the most validated tracer in the imaging of IFD.
Over the last decades, the population at risk for invasive fungal disease (IFD) has increased because of medical therapy advances and diseases compromising patients' immune systems. The high morbidity and mortality associated with invasive fungal disease in the immunocompromised present the challenge of early diagnosis of the IFD and the need to closely monitor the infection during treatment. The definitive diagnosis of invasive fungal disease based on culture or histopathological methods often has reduced diagnostic accuracy in the immunocompromised and may be very invasive. Less invasive and indirect evidence of the fungal infection by serology and imaging has been used for the early diagnosis of fungal infection before definitive results are available or when the definitive methods of diagnosis are suboptimal. Imaging in invasive fungal disease is a non-invasive biomarker that helps in the early diagnosis of invasive fungal disease but helps follow-up the infection during treatment. Different imaging modalities are used in the workup to evaluate fungal disease. The different imaging modalities have advantages and disadvantages at different sites in the body and may complement each other in the management of IFD. Positron emission tomography integrated with computed tomography with [18F]Fluorodeoxyglucose (FDG PET/CT) has helped manage IFD. The combined functional data from PET and anatomical data from the CT from almost the whole body allows noninvasive evaluation of IFD and provides a semiquantitative means of assessing therapy. FDG PET/CT adds value to anatomic-based only imaging modalities. The nonspecificity of FDG uptake has led to the evaluation of other tracers in the assessment of IFD. However, these are mainly still at the preclinical level and are yet to be translated to humans. FDG PET/CT remains the most widely evaluated radionuclide-based imaging modality in IFD management. The limitations of FDG PET/CT must be well understood, and more extensive prospective studies in uniform populations are needed to validate its role in the management of IFD that can be international guidelines.
Molecular Imaging of Tuberculosis
2023, Seminars in Nuclear Medicine
Citation Excerpt :
Siderophores produced by the microbes are utilized to extract gallium from the gallium-transferrin complex in a manner analogous to iron extraction. Gallium-67, a single-photon emission tomography tracer, is one of the earliest radionuclides used in TB imaging, exploring this essential requirement for iron in human TB infection.18,118,119 The sub-optimal image quality of Gallium-67 scintigraphy, the high radiation burden it impacts on patients, the long duration of imaging (48-72 hours post tracer injection), and the introduction of FDG PET/CT to the clinics all contributed to the limited utilization of Gallium-67 scintigraphy for TB imaging.
Despite the introduction of many novel diagnostic techniques and newer treatment agents, tuberculosis (TB) remains a major cause of death from an infectious disease worldwide. With about a quarter of humanity harboring Mycobacterium tuberculosis, the causative agent of TB, the current efforts geared towards reducing the scourge due to TB must be sustained. At the same time, newer alternative modalities for diagnosis and treatment response assessment are considered. Molecular imaging entails the use of radioactive probes that exploit molecular targets expressed by microbes or human cells for imaging using hybrid scanners that provide both anatomic and functional features of the disease being imaged. Fluorine-18 fluorodeoxyglucose (FDG) is the most investigated radioactive probe for TB imaging in research and clinical practice. When imaged with positron emission tomography interphase with computed tomography (PET/CT), FDG PET/CT performs better than sputum conversion for predicting treatment outcome. At the end of treatment, FDG PET/CT has demonstrated the unique ability to identify a subset of patients declared cured based on the current standard of care but who still harbor live bacilli capable of causing disease relapse after therapy discontinuation. Our understanding of the pathogenesis and evolution of TB has improved significantly in the last decade, owing to the introduction of FDG PET/CT in TB research. FDG is a non-specific probe as it targets the host inflammatory response to Mycobacterium tuberculosis, which is not specifically different in TB compared with other infectious conditions. Ongoing efforts are geared towards evaluating the utility of newer probes targeting different components of the TB granuloma, the hallmark of TB lesions, including hypoxia, neovascularization, and fibrosis, in TB management. The most exciting category of non-FDG PET probes developed for molecular imaging of TB appears to be radiolabeled anti-tuberculous drugs for use in studying the pharmacokinetic characteristics of the drugs. This allows for the non-invasive study of drug kinetics in different body compartments concurrently, providing an insight into the spatial heterogeneity of drug exposure in different TB lesions. The ability to repeat molecular imaging using radiolabeled anti-tuberculous agents also offers an opportunity to study the temporal changes in drug kinetics within the different lesions during treatment.
Monitoring Response to Therapy
2018, Seminars in Nuclear Medicine
Citation Excerpt :
It has the potential of being used in monitoring response. In the past, tracers such as Ga67 citrate, thallium, and Tc-99m MIBI have been used in assessing response in fungal infections, osteomyelitis, and even TB.113-115 New tracers that may be specific to organisms have been evaluated in their role for monitoring response such as Tc-99m-labeled fluconazole or Tc-labeled chitin or chitinase.116-118
Monitoring response to treatment is a key element in the management of infectious diseases, yet controversies still persist on reliable biomarkers for noninvasive response evaluation. Considering the limitations of invasiveness of most diagnostic procedures and the issue of expression heterogeneity of pathology, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively. The usefulness of ¹⁸F-FDG-PET/CT in assessing treatment response in infectious diseases is more promising than for conventional imaging. However, there are currently no clinical criteria or recommended imaging modalities to objectively evaluate the effectiveness of antimicrobial treatment. Therapeutic effectiveness is currently gauged by the patient's subjective clinical response. In this review, we present the current studies for monitoring treatment response, with a focus on Mycobacterium tuberculosis, as it remains a major worldwide cause of morbidity and mortality. The role of molecular imaging in monitoring other infections including spondylodiscitis, infected prosthetic vascular grafts, invasive fungal infections, and a parasitic disease is highlighted. The role of functional imaging in monitoring lipodystrophy associated with highly active antiretroviral therapy for human immunodeficiency virus is considered. We also discuss the key challenges and emerging data in optimizing noninvasive response evaluation.
Ocular Sarcoidosis
2018, Sarcoidosis: A Clinician's Guide
Sarcoidosis is a multisystem disorder characterized by the formation of noncaseating granulomas in the affected organs. The lungs are the most commonly affected organs, followed by the skin and eyes. Ocular involvement occurs in about a quarter of patients with sarcoidosis, often early in the disease course. Uveitis is the most common manifestation of ocular sarcoidosis, but any part of the eye can be affected. This chapter reviews current knowledge about the pathogenesis of sarcoidosis, epidemiologic trends in the United States and worldwide, as well as the different clinical manifestations. Diagnostic tools are reviewed, and a diagnostic algorithm is proposed. Different treatment options are reviewed, with reference made to the authors' experience and preferences.
Atypical Infectious Diseases
2016, Diagnostic Imaging: Nuclear Medicine
FDG PET imaging in sarcoidosis
2013, Seminars in Nuclear Medicine
The objective of this review is to highlight the clinical utility of FDG-PET/CT for evaluation of patients with chronic sarcoidosis. The emphasis was on the potential advantages and disadvantages of this technique in these patients based on which recommendations were made. The advantage of FDG-PET/CT technique is that it can visualize FDG accumulation in activated inflammatory cells and simultaneously provide PET and CT images. Of particular interest is the use of FDG-PET/CT for the staging and identification of occult sites and sites suitable for biopsy and for the assessment of inflammatory active sarcoidosis in patients with prolonged symptoms, especially when other markers of the disease are within normal values. FDG-PET/CT also provides a better visualization of extrathoracic sites of active sarcoidosis, such as in the bones, liver, spleen, and retroperitoneal lymph nodes. The use of FDG-PET/CT is of special interest in cardiac sarcoidosis because this potentially life-threatening disease is sometimes present in asymptomatic patients. FDG-PET/CT also has a role in the clinical management of patients with chronic persistent sarcoidosis, such as for planning treatment, monitoring response, and long-term follow-up. The limitations of FDG-PET/CT in patients with sarcoidosis are discussed in the context of a “sarcoidosis-lymphoma syndrome” and potentially excessive radiation exposure. Further prospective multicentre studies are needed to refine the clinical applications of FDG-PET/CT in patients with sarcoidosis and drive the field forward.

View all citing articles on Scopus

View full text

Gallium and other agents in diseases of the lung

Chest

Radiol Clin North Am

Blood

J Thorac Cardiovasc Surg

Chest

Clin Chest Med

Chest

Clin Chest Med

Clin Chest Med

Chest

Chest

Semin Nucl Med

Chest

Chest

Semin Nucl Med

Tumor scanning with Ga-67 citrate

J Nucl Med

Gallium-67 citrate scanning in neoplastic and inflammatory lesions

Br J Radiol

Gallium-67 for localization of septic lesions

Ann Intern Med

Ga-67 scintigraphy in B-cell non-Hodgkin's lymphoma: Correlation of Ga-67 uptake with histology and transferrin receptor expression

J Nucl Med

Gallium scintigraphy in tumor diagnosis and management

Demonstration of lactoferrin in tumor tissue from two patients with positive gallium scans

J Nucl Med

The association of 67Ga and lactoferrin

J Nucl Med

Mechanism of gallium localization in inflammatory lesions

J Nucl Med

Accumulation of indium-111 labeled neutrophils and gallium-67 citrate in rabbit abscesses

J Nucl Med

Comparisons of scintigraphy with In-111 leukocytes and Ga-67 in the diagnosis of occult sepsis

J Nucl Med

The relationship between 67Ga accumulation and ATP metabolism in tumor cells in vitro

Eur J Nucl Med

A Clinician's Guide to Nuclear Medicine

Thallium-201 chloride: A tumor imaging agent

Comparison of gallium-67 citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma

J Nucl Med

Tl-201 scintigraphy in bone and soft tissue sarcoma: Evaluation of tumor mass and viability

J Nucl Med

Serial Tl-201 scintigraphy in osteosarcoma: Correlation with tumor necrosis after preoperative chemotherapy

Clin Orthop

Effectiveness of planar image and single photon emission tomography of thallium-201 compared with gallium-67 in patients with primary lung cancer

Eur J Nucl Med

Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up

J Nucl Med

Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer

J Nucl Med

A Clinician's Guide to Nuclear Medicine

Gallium scintigraphy in tumor diagnosis and management

The relative roles of gallium-67 citrate scanning and lymphangiography in the current management of malignant lymphoma

Cancer

Planning mantle radiation therapy in patients with Hodgkin's disease: Role of gallium-67 scintigraphy

AJR Am J Roentgenol

Lymphoma: Evaluation with Ga-67 SPECT

Radiology

Diagnostic role of gallium scanning in the management of lymphoma with mediastinal involvement

Haematologica

Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

Med Oncol

Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma

Leuk Lymphoma

Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study

Cancer

Pediatric solid tumors: Evaluation by gallium-67 SPECT studies

J Nucl Med

The role of thallium scintigraphy in excluding malignancy in bone

Nucl Med Commun

Pulmonary Kaposi sarcoma in patients with AIDS: Scintigraphic diagnosis with sequential thallium and gallium scanning

Radiology

Reliability of gallium scan chest radiography compared to mediastinoscopy for evaluating mediastinal spread in lung cancer

Am Rev Respir Dis

Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer

Cancer

Lack of clinical significance of gallium-67 uptake in non-small cell lung cancer

Eur J Respir Dis

Evaluation of 99mTc-MIBI to predict chemotherapeutic response in patients with small cell lung carcinoma

The association of ⁶⁷Ga and lactoferrin

Evaluation of ^99mTc-MIBI to predict chemotherapeutic response in patients with small cell lung carcinoma